Market cap
$12,569 Mln
Market cap
$12,569 Mln
Revenue (TTM)
$4,152 Mln
P/E Ratio
32
P/B Ratio
1.5
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
0 %
ROCE
3.5 %
Industry P/E
53.55
EV/EBITDA
13.9
Debt to Equity
0.2
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
195,114,398
CFO
$5,856.23 Mln
EBITDA
$5,279.27 Mln
Net Profit
$5,589.90 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Cooper Companies Inc (COO)
| -- | -- | -- | -- | -12.5 | -8.9 | 5.0 |
|
BSE Sensex
| -9.5 | 5.5 | -6.0 | -4.3 | 8.7 | 9.9 | 11.5 |
|
S&P 100
| 1.9 | 9.5 | 3.1 | 35.3 | 23.1 | 13.2 | 14.3 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|---|
|
Cooper Companies Inc (COO)
| -21.1 | 15.3 | 13.1 | 26.2 | 16.7 | 24.6 | 30.4 |
|
S&P 100
| -22.1 | 27.6 | 19.3 | 29.5 | -5.8 | 19.3 | 8.8 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Cooper Companies Inc (COO)
|
64.5 | 12,569.3 | 4,151.9 | 401.4 | 11.1 | 4.8 | 32 | 1.5 |
| 116.3 | 32,654.7 | 7,065.0 | 1,290.0 | 21.8 | 19.4 | 25.5 | 4.7 | |
| 2.1 | 6.9 | 0.0 | -8.5 | -89,802.3 | -292.9 | -- | 2.6 | |
| 83.3 | 107,576.7 | 35,484.0 | 4,614.0 | 17.7 | 9.5 | 23.4 | 2.2 | |
| 158.9 | 26,486.9 | 3,195.3 | 908.9 | 21.0 | 13.9 | 28.7 | 3.5 |
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and... multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia. Its CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage. This segment offers Paragard, a hormone-free intrauterine device; and fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals and clinics, and authorized resellers. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California. Read more
President, CEO & Non-Independent Director
Mr. Albert G. White III
President, CEO & Non-Independent Director
Mr. Albert G. White III
Headquarters
San Ramon, CA
Website
The share price of Cooper Companies Inc (COO) is $64.45 (NYSE) and $64.48 (NASDAQ) as of 24-Apr-2026 13:44 EDT. Cooper Companies Inc (COO) has given a return of -12.54% in the last 3 years.
The P/E ratio of Cooper Companies Inc (COO) is 32.05 times as on 24-Apr-2026, a 40 discount to its peers’ median range of 53.55 times.
The P/B ratio of Cooper Companies Inc (COO) is 1.52 times as on 24-Apr-2026, a 54 discount to its peers’ median range of 3.27 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
--
|
--
|
|
2024
|
--
|
--
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
The 52-week high and low of Cooper Companies Inc (COO) are Rs 64.80 and Rs 63.72 as of 25-Apr-2026.
Cooper Companies Inc (COO) has a market capitalisation of $ 12,569 Mln as on 24-Apr-2026. As per SEBI classification, it is a Large Cap company.
Before investing in Cooper Companies Inc (COO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.